Ana Carolina Pavanelli

Mrs. Ana Carolina Pavanelli


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2021 in Genes
Verified
Journal Article
Open access
PDF file
APAna Carolina Pavanelli
Ana Carolina Pavanelli
FMFlavia Mangone
Flavia Mangone
LBLuciana Rodrigues Carvalho Barros
Luciana Rodrigues Carvalho Barros
Juliana Machado-RugoloJuliana Machado-Rugolo
Juliana Machado-Rugolo
VERA CAPELOZZIVERA CAPELOZZI
VERA CAPELOZZI
MNMaria Nagai
Maria Nagai
Abnormal long non-coding RNAs (lncRNAs) expression has been documented to have oncogene or tumor suppressor functions in the development and progression of cancer, emerging as promising independent biomarkers for molecular cancer stratification and patients’ prognosis. Examining the relationship between lncRNAs and the survival rates in malignancies creates new scenarios for precision medicine and targeted therapy. Breast cancer (BRCA) is a heterogeneous malignancy. Despite advances in its molecular classification, there are still gaps to explain in its multifaceted presentations and a substantial lack of biomarkers that can better predict patients’ prognosis in response to different therapeutic strategies. Here, we performed a re-analysis of gene expression data generated using cDNA microarrays in a previous study of our group, aiming to identify differentially expressed lncRNAs (DELncRNAs) with a potential predictive value for response to treatment with taxanes in breast cancer patients. Results revealed 157 DELncRNAs (90 up- and 67 down-regulated). We validated these new biomarkers as having prognostic and predictive value for breast cancer using in silico analysis in public databases. Data from TCGA showed that compared to normal tissue, MIAT was up-regulated, while KCNQ1OT1, LOC100270804, and FLJ10038 were down-regulated in breast tumor tissues. KCNQ1OT1, LOC100270804, and FLJ10038 median levels were found to be significantly higher in the luminal subtype. The ROC plotter platform results showed that reduced expression of these three DElncRNAs was associated with breast cancer patients who did not respond to taxane treatment. Kaplan–Meier survival analysis revealed that a lower expression of the selected lncRNAs was significantly associated with worse relapse-free survival (RFS) in breast cancer patients. Further validation of the expression of these DELncRNAs might be helpful to better tailor breast cancer prognosis and treatment.

1 November 2021 in Toxicology
Verified
Journal Article
Closed access
JBJôse Mára de Brito
Jôse Mára de Brito
Francine AlmeidaFrancine Almeida
Francine Almeida
FAFernanda Magalhães Arantes-Costa
Fernanda Magalhães Arantes-Costa
EGEliane Tigre Guimarães
Eliane Tigre Guimarães
AMAdriana Morgan
Adriana Morgan
TMTHAIS MAUAD
THAIS MAUAD